Breast Cancer Version 2.2015

Gradishar, William J.; Anderson, Benjamin O.; Balassanian, Ronald; Blair, Sarah L.; Burstein, Harold J.; Cyr, Amy; Elias, Anthony; Farrar, William B.; Forero, Andres; Giordano, Sharon H.; Goetz, Matthew P.; Goldstein, Lori J.; Hudis, Clifford A.; Isakoff, Steven J.; Marcom, P. Kelly; Mayer, Ingrid A.; McCormick, Beryl; Moran, Meena S.; Patel, Sameer A.; Pierce, Lori J.; Reed, Elizabeth; Salerno, Kilian E.; Schwartzberg, Lee S.; Smith, Karen L.; Smith, Mary Lou; Soliman, Hatem; Somlo, George; Telli, Melinda L.; Ward, John H.; Shead, Dorothy A.; Kumar, Rashmi

doi:10.6004/jnccn.2015.0060

Cited by 187 publications

(140 citation statements)

References 52 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…For women who are postmenopausal at breast cancer diagnosis, it is recommended that adjuvant ET include an aromatase inhibitor (AI) [27,28]-exemestane, anastrozole, or letrozole [29]-unless contraindicated. For women who are premenopausal at breast cancer diagnosis, tamoxifen with or without ovarian suppression (OS) or an AI plus OS are the preferred adjuvant ET [26]. Both tamoxifen and AIs are taken as a once-a-day oral medication for 5 years, with consideration of up to 5 years of additional ET thereafter [30,31].…”

Section: Introductionmentioning

confidence: 99%

“…[24,25]. For these patients, most of whom will die of non-breast cancer causes, it is recommended that adjuvant therapy include endocrine treatment [26,27]. For women who are postmenopausal at breast cancer diagnosis, it is recommended that adjuvant ET include an aromatase inhibitor (AI) [27,28]-exemestane, anastrozole, or letrozole [29]-unless contraindicated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Nyrop

Muss

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9-17 %), stable weight (47-64 %), and gained weight (27-36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Nyrop

Muss

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…However, several chemotherapy regimens exist that also produce substantial clinical benefit as first-line therapy for HR?ve MBC. In some instances, for example, in patients with extensive visceral metastasis, chemotherapy can even be considered as the preferred option [7][8][9][10][11]. Up to now, chemotherapy has not been compared with endocrine therapy in combination with targeted therapy (e.g., EXE/EVE) as first-line treatment for MBC in randomized trials; only two trials are ongoing comparing endocrine therapy plus a target agent (EVE or palbociclib) versus capecitabine (see: www.clin icaltrial.gov), but the data are not ready yet.…”

Section: Introductionmentioning

confidence: 99%

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Generali

Venturini

Rognoni

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining randomization of individual studies. The method enables "direct" evidence (i.e., evidence from studies directly comparing two interventions) and "indirect" evidence (i.e., evidence from studies that do not compare the two interventions directly) to be pooled under the assumption of evidence consistency. We used NMA to evaluate progression-free survival (PFS) and time to progression (TTP) curves in 34 studies, and response rate (RR) and the hazard ratios (HRs) of the PFS/TTP in 36 studies. A number needed to treat (NNT) analysis was also performed as well as descriptive comparison of reported toxicities. The NMA for PFS/TTP curves and for HR shows EXE/EVE is more efficacious than capecitabine plus sunitinib, CMF, megestrol acetate and tamoxifen, with an average of related-PFS/TTP difference ranging from about 10 months for capecitabine plus sunitinib to more than 6 months for tamoxifen. The NMA for overall RR shows that EXE/EVE provides a better RR than bevacizumab plus capecitabine, capecitabine, capecitabine plus sorafenib, capecitabine plus sunitinib, CMF, gemcitabine plus epirubicin plus paclitaxel, EVE plus tamoxifen, EXE, FEC, megestrol acetate, mitoxantrone, and tamoxifen. Finally, the NMA for NNT shows that EXE/EVE is more beneficial as compared to BMF, capecitabine, capecitabine plus sunitinib, CMF, FEC, megestrol acetate, mitoxantrone, and tamoxifen. The combination of EXE/EVE as first- or second-line therapy for ER+ve/HER2-ve metastatic breast cancer is more efficacious than several chemotherapy regimens that were reported in the literature. Toxicities also favored EXE/EVE in most instances.

show abstract

“…In breast cancer, whether there is metastasis of the axillary lymph nodes affects the decision of whether to perform lymph node dissection and radiotherapy (6)(7)(8). However, to date, few methods can predict lymphatic metastasis.…”

Section: Discussionmentioning

confidence: 99%

Positive Predictive Value of Mammographic Lymphography in the Evaluation of Patients with Breast Cancer

Zhang

Lü

et al. 2016

Academic Radiology

View full text Add to dashboard Cite

Breast Cancer Version 2.2015

Cited by 187 publications

References 52 publications

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Positive Predictive Value of Mammographic Lymphography in the Evaluation of Patients with Breast Cancer

Contact Info

Product

Resources

About